What is the treatment for Herpes Simplex Virus (HSV) 1?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of HSV-1 Infection

For HSV-1 infections, initiate oral antiviral therapy with acyclovir, valacyclovir, or famciclovir at the first sign of symptoms, with specific dosing regimens depending on whether this is a first episode, recurrent outbreak, or requires suppressive therapy. 1

First Clinical Episode

For initial HSV-1 infections, treatment duration is longer than recurrent episodes:

  • Acyclovir 400 mg orally three times daily for 7-10 days 1
  • Alternative: Acyclovir 200 mg orally five times daily for 7-10 days 1
  • Alternative: Famciclovir 250 mg orally three times daily for 7-10 days 1
  • Alternative: Valacyclovir 1 g orally twice daily for 7-10 days 1

Extend treatment beyond 10 days if healing is incomplete 1. For herpes proctitis or severe oral infection, higher dosing may be required (acyclovir 400 mg orally five times daily) 1.

Recurrent Episodes (Episodic Therapy)

Treatment must be initiated at the first sign of prodrome or within 1 day of lesion onset for maximum effectiveness 1. Standard regimens include:

  • Acyclovir 400 mg orally three times daily for 5 days 2, 1
  • Alternative: Acyclovir 800 mg orally twice daily for 5 days 2, 1
  • Alternative: Acyclovir 800 mg orally three times daily for 2 days 1
  • Alternative: Famciclovir 125 mg orally twice daily for 5 days 2
  • Alternative: Valacyclovir 500 mg orally twice daily for 5 days 2

For herpes labialis (cold sores), single-day high-dose regimens have shown effectiveness:

  • Famciclovir 1500 mg as a single dose 1
  • Famciclovir 750 mg twice daily for 1 day 1
  • Valacyclovir 2 g twice daily for 1 day 1

Suppressive Therapy

For patients with frequent recurrences (≥6 episodes per year), daily suppressive therapy reduces recurrence frequency by ≥75% 2, 1:

  • Acyclovir 400 mg orally twice daily 2, 1
  • Alternative: Valacyclovir 500 mg once daily 2, 1
  • Alternative: Valacyclovir 1 g once daily (for patients with ≥10 recurrences per year) 1
  • Alternative: Famciclovir 250 mg orally twice daily 2

Safety has been documented for acyclovir for up to 6 years and valacyclovir/famciclovir for 1 year 2, 1. After 1 year of continuous suppressive therapy, reassess the need for ongoing treatment 2.

Severe Disease Requiring Hospitalization

For severe HSV-1 disease with complications such as disseminated infection, pneumonitis, hepatitis, or CNS involvement (meningitis, encephalitis):

  • Acyclovir 5-10 mg/kg IV every 8 hours for 5-7 days or until clinical resolution 2

Special Populations

Immunocompromised Patients (Including HIV-Infected)

Immunocompromised patients require longer courses of therapy and closer monitoring, as healing may be slower and treatment failures more common 2:

  • Higher doses are often beneficial: Acyclovir 400 mg orally three to five times daily 2
  • Continue therapy until clinical resolution is attained 2
  • For severe cases: Acyclovir 5 mg/kg IV every 8 hours 2

If lesions persist despite acyclovir treatment, suspect resistance 2. For proven or suspected acyclovir-resistant strains:

  • Foscarnet 40 mg/kg IV every 8 hours until clinical resolution 2
  • Alternative: Topical cidofovir gel 1% applied once daily for 5 consecutive days 2

Note that all acyclovir-resistant strains are resistant to valacyclovir, and most are resistant to famciclovir 2.

Pregnancy

The safety of systemic acyclovir and valacyclovir in pregnancy has not been fully established, though current registry findings do not indicate increased risk for major birth defects 2.

Critical Clinical Considerations

Topical acyclovir is substantially less effective than oral therapy and should not be used 2, 1, 3.

Antiviral medications control symptoms but do not eradicate latent virus or affect the risk, frequency, or severity of recurrences after discontinuation 2, 1.

Suppressive therapy reduces but does not eliminate asymptomatic viral shedding 2, so transmission risk persists even on treatment.

Patient Counseling

Educate patients about:

  • The natural history of HSV-1 infection and potential for recurrent episodes 1
  • Asymptomatic viral shedding and transmission risk 1
  • Abstaining from sexual activity when lesions or prodromal symptoms are present 3
  • Using condoms during all sexual exposures with new or uninfected partners 3

References

Guideline

Treatment of Herpes Simplex Virus (HSV) 1

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment for Recurrent Genital Herpes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.